CA3091642A1 - Agents and methods for treating dysproliferative diseases - Google Patents

Agents and methods for treating dysproliferative diseases Download PDF

Info

Publication number
CA3091642A1
CA3091642A1 CA3091642A CA3091642A CA3091642A1 CA 3091642 A1 CA3091642 A1 CA 3091642A1 CA 3091642 A CA3091642 A CA 3091642A CA 3091642 A CA3091642 A CA 3091642A CA 3091642 A1 CA3091642 A1 CA 3091642A1
Authority
CA
Canada
Prior art keywords
alkyl
compound
cancer
haloalkyl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3091642A
Other languages
English (en)
French (fr)
Inventor
Yoshiyuki Fukase
Mark Duggan
Hans-Guido Wendel
Kamini SINGH
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Memorial Sloan Kettering Cancer Center
Original Assignee
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memorial Sloan Kettering Cancer Center filed Critical Memorial Sloan Kettering Cancer Center
Publication of CA3091642A1 publication Critical patent/CA3091642A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • C07F9/65517—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring condensed with carbocyclic rings or carbocyclic ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Furan Compounds (AREA)
CA3091642A 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases Pending CA3091642A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862632372P 2018-02-19 2018-02-19
US62/632,372 2018-02-19
PCT/US2019/018441 WO2019161345A1 (en) 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases

Publications (1)

Publication Number Publication Date
CA3091642A1 true CA3091642A1 (en) 2019-08-22

Family

ID=67619605

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3091642A Pending CA3091642A1 (en) 2018-02-19 2019-02-18 Agents and methods for treating dysproliferative diseases

Country Status (9)

Country Link
US (2) US12215090B2 (https=)
EP (1) EP3755693B1 (https=)
JP (1) JP2021513963A (https=)
KR (1) KR20200123184A (https=)
CN (1) CN112351977A (https=)
AU (1) AU2019221837B2 (https=)
CA (1) CA3091642A1 (https=)
IL (1) IL276639A (https=)
WO (1) WO2019161345A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149942B (zh) * 2021-02-10 2023-06-02 贵州省中国科学院天然产物化学重点实验室(贵州医科大学天然产物化学重点实验室) 一种洛克米兰醇酚羟基衍生物、其制备方法和应用
WO2022221519A1 (en) * 2021-04-14 2022-10-20 Memorial Sloan-Kettering Cancer Center Synthetic rocaglates with broad-spectrum antiviral activities and uses thereof
CN121712777A (zh) * 2023-08-18 2026-03-20 皇家学术促进机构麦吉尔大学 Rna解旋酶抑制剂

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19934952A1 (de) * 1998-07-30 2000-02-03 Novartis Ag Cyclopentabenzofuran-Derivate
AUPQ866500A0 (en) 2000-07-05 2000-08-03 Exgenix Operations Pty Ltd Therapeutic compounds and methods
US7816544B2 (en) 2004-03-23 2010-10-19 Trustees Of Boston University Synthesis of rocaglamide natural products via photochemical generation of oxidopyrylium species
DE102004024504A1 (de) 2004-05-18 2006-02-16 Bayer Healthcare Ag Neue Cylopenta[b]benzofuran-Derivate und ihre Verwendung
WO2006007634A1 (en) 2004-07-16 2006-01-26 Cerylid Biosciences Ltd Processes and intermediates
CA2652873A1 (en) 2006-05-22 2007-12-06 Trustees Of Boston University Asymmetric synthesis of rocaglamides via enantioselective photocycloaddition mediated by chiral bronsted acids
US20100168084A1 (en) 2008-05-08 2010-07-01 Huber L Julie Therapeutic compounds and related methods of use
EP2189158A1 (en) 2008-11-20 2010-05-26 DKFZ Deutsches Krebsforschungszentrum, Stiftung des Öffentlichen Rechts Combination of rocaglamide and apoptosis inducing substances for the treatment of cancer
EP2189453A1 (en) 2008-11-25 2010-05-26 Université Louis Pasteur Rocaglaol derivatives as cardioprotectant agents
WO2011140334A2 (en) * 2010-05-06 2011-11-10 Trustees Of Boston University Compounds, methods of making or identifying compounds, and uses thereof
US20140255432A1 (en) 2011-07-27 2014-09-11 Ohio State Innovation Foundation Silvestrol, silvestrol analogs and uses thereof
WO2013170257A1 (en) 2012-05-11 2013-11-14 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
WO2015085221A2 (en) 2013-12-05 2015-06-11 Memorial Sloan Kettering Cancer Center Methods for identifying anti-cancer compounds
JP6306481B2 (ja) 2014-03-17 2018-04-04 株式会社神戸製鋼所 延性及び曲げ性に優れた高強度冷延鋼板および高強度溶融亜鉛めっき鋼板、並びにそれらの製造方法
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
EP3888658B1 (en) * 2015-11-25 2023-12-27 Effector Therapeutics, Inc. Eif4-a-inhibiting compounds and methods related thereto
US10639378B2 (en) * 2016-06-06 2020-05-05 Genentech, Inc. Silvestrol antibody-drug conjugates and methods of use

Also Published As

Publication number Publication date
US20200392099A1 (en) 2020-12-17
US12215090B2 (en) 2025-02-04
EP3755693A4 (en) 2021-08-04
AU2019221837B2 (en) 2024-08-01
IL276639A (en) 2020-09-30
WO2019161345A1 (en) 2019-08-22
AU2019221837A1 (en) 2020-09-03
KR20200123184A (ko) 2020-10-28
CN112351977A (zh) 2021-02-09
EP3755693A1 (en) 2020-12-30
JP2021513963A (ja) 2021-06-03
EP3755693B1 (en) 2024-06-12
US20250361218A1 (en) 2025-11-27

Similar Documents

Publication Publication Date Title
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
CN105646389B (zh) 一种作为吲哚胺-2,3-双加氧酶抑制剂的氨基磺酸脂及其制备方法和用途
WO2016041489A1 (zh) 一种吲哚胺-2,3-双加氧酶抑制剂及其制备方法
EA037521B1 (ru) Противогрибковые соединения и способы их получения
WO2003074525A1 (fr) Compose heterocyclique azote
CN101006090A (zh) 4[[(7r)－8－环戊基－7－乙基－5,6,7,8－四氢－5－甲基－4－6－氧代－2－哌啶基]氨基]－3－甲氧基－n－(1－甲基－4－哌啶基)－苯甲酰胺的水合物及多晶型物，其制造方法及其作为药物的用途
US9902698B2 (en) 2-[[[2-[(Hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
CN112566900A (zh) 免疫调节剂及其组合物和制备方法
WO2022105852A1 (zh) 三嗪二酮类衍生物、其制备方法及其在医药上的应用
EP4482579B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
KR19980703022A (ko) 3-(비스-치환 페닐메틸렌)옥신돌 유도체
UA99927C2 (uk) Медикамент, який є активним при невропатичному болі
PL185709B1 (pl) Nowy monohydrat polimorfu II 6-N-(L-Ala-L-Ala)-trowafloksacyny i środek farmaceutyczny
JPH0449230A (ja) トロンボキサンＡ↓ｚ拮抗剤
HK1167647B (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-n-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzene- sulfonate, crystals of same, polymorphs thereof, and processes for production thereof
WO2006134963A1 (ja) オキサルル酸誘導体を含有する線維性疾患用剤

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20240216

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250904

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-2-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251104

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260102

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260401